Login to Your Account

Good 'Fortuna'

$25M series B positions regenerative med firm for human trials in PD, SCI

By Marie Powers
News Editor

Wednesday, November 8, 2017

Fortuna Fix Inc. is seeking to become the first company to advance a program into the clinic that uses autologous neural stem cells produced by direct reprogramming, dubbed drNPCs, to replace neuronal tissue lost to neurodegeneration or brain trauma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription